Myriad Genetics, Inc. (LON: 0K3W)

Market Cap	907.69M
Revenue (ttm)	614.49M
Net Income (ttm)	-86.55M
Shares Out	n/a
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16
Average Volume	464
Open	12.77
Previous Close	12.65
Day's Range	12.60 - 12.77
52-Week Range	12.60 - 24.13
Beta	1.78
RSI	34.53
Earnings Date	Feb 25, 2025

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or sus...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 2,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K3W

Financial Performance

In 2023, Myriad Genetics's revenue was $753.20 million, an increase of 11.03% compared to the previous year's $678.40 million. Losses were -$263.30 million, 135.1% more than in 2022.

Financial numbers in USD